Literature DB >> 33887303

Noninvasive low-grade papillary urothelial carcinoma with degenerative nuclear atypia: a grading pitfall.

Andres Matoso1, Vamsi Parimi2, Jonathan I Epstein3.   

Abstract

Noninvasive low-grade papillary urothelial carcinoma is a papillary neoplasm with orderly appearance and mild nuclear pleomorphism. Some cases show significant nuclear pleomorphism with degenerative atypia leading to grading difficulties. A retrospective review of the pathology files identified 16 cases diagnosed as noninvasive low-grade papillary urothelial carcinoma with degenerative atypia. Fifteen cases were consults. The average age was 46 years (range 19-78). The average size was 1.7 cm (range: 0.3-3.5). The submitting diagnoses in consults were noninvasive high-grade papillary urothelial carcinoma (n = 6), condyloma (n = 1), atypical papillary lesion (n = 1), prominent umbrella cells (n = 1), and not given (n = 6). Ki-67 proliferation rate was <5% in 10 of 10 cases (100%), and the cells with large atypical nuclei were negative. Microscopically, there were scattered cells with nuclei larger than 5 times the size of stromal lymphocytes but displayed smudgy chromatin and occasional multinucleation and intranuclear vacuoles. Next-generation sequencing identified the following mutations: HRAS (n = 4), FGFR3 (n = 3), KRAS (n = 3), BRAF (n = 1), PDGFRA (n = 1), and PIK3CA (n = 1). Other deleterious mutations were identified, but none in genes characteristic of high-grade tumors. Follow-up was available in 6 patients (median 32 months). One patient recurred with a noninvasive low-grade papillary urothelial carcinoma 20 months after the index case. All the remaining patients had no evidence of disease at the last follow-up. No patient died or had disease progression. The combination of preservation of polarity, low mitotic activity, Ki-67 <5% with the larger atypical nuclei negative for Ki-67, along with nuclear atypia that is degenerative are features used to classify these tumors as low grade.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Degenerative atypia; Grade; Ki67; Papillary urothelial carcinoma

Mesh:

Substances:

Year:  2021        PMID: 33887303      PMCID: PMC9281537          DOI: 10.1016/j.humpath.2021.04.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.526


  29 in total

Review 1.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

Review 2.  Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis.

Authors:  X Liu; W Zhang; D Geng; J He; Y Zhao; L Yu
Journal:  Genet Mol Res       Date:  2014-02-20

3.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Authors:  C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  Mixed high and low grade bladder tumors--are they clinically high or low grade?

Authors:  Ofer N Gofrit; Galina Pizov; Amos Shapiro; Mordechai Duvdevani; Vladimir Yutkin; Ezekiel H Landau; Kevin C Zorn; Guy Hidas; Dov Pode
Journal:  J Urol       Date:  2013-12-05       Impact factor: 7.450

5.  Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.

Authors:  Eugene J Pietzak; Aditya Bagrodia; Eugene K Cha; Esther N Drill; Gopa Iyer; Sumit Isharwal; Irina Ostrovnaya; Priscilla Baez; Qiang Li; Michael F Berger; Ahmet Zehir; Nikolaus Schultz; Jonathan E Rosenberg; Dean F Bajorin; Guido Dalbagni; Hikmat Al-Ahmadie; David B Solit; Bernard H Bochner
Journal:  Eur Urol       Date:  2017-06-03       Impact factor: 20.096

6.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

Review 7.  Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer.

Authors:  Mahul B Amin; Steven C Smith; Victor E Reuter; Jonathan I Epstein; David J Grignon; Donna E Hansel; Oscar Lin; Jesse K McKenney; Rodolfo Montironi; Gladell P Paner; Hikmat A Al-Ahmadie; Ferran Algaba; Syed Ali; Isabel Alvarado-Cabrero; Lukas Bubendorf; Liang Cheng; John C Cheville; Glen Kristiansen; Richard J Cote; Brett Delahunt; John N Eble; Elizabeth M Genega; Christian Gulmann; Arndt Hartmann; Cord Langner; Antonio Lopez-Beltran; Cristina Magi-Galluzzi; Jorda Merce; George J Netto; Esther Oliva; Priya Rao; Jae Y Ro; John R Srigley; Satish K Tickoo; Toyonori Tsuzuki; Saleem A Umar; Theo Van der Kwast; Robert H Young; Mark S Soloway
Journal:  Mod Pathol       Date:  2014-11-21       Impact factor: 7.842

8.  Discriminant nuclear features of renal oncocytoma and chromophobe renal cell carcinoma. Analysis of their potential utility in the differential diagnosis.

Authors:  S K Tickoo; M B Amin
Journal:  Am J Clin Pathol       Date:  1998-12       Impact factor: 2.493

Review 9.  Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.

Authors:  Bas W G van Rhijn; Maximilian Burger; Yair Lotan; Eduardo Solsona; Christian G Stief; Richard J Sylvester; J Alfred Witjes; Alexandre R Zlotta
Journal:  Eur Urol       Date:  2009-06-26       Impact factor: 20.096

10.  Symplastic leiomyomas of the scrotum: a comparative study to usual leiomyomas and leiomyosarcomas.

Authors:  Andres Matoso; Sonja Chen; Jose A Plaza; Adeboye O Osunkoya; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2014-10       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.